JohnBLiaoMDPhD

Gynecologic Oncology

Associate Professor, Obstetrics & Gynecology, University of Washington School of Medicine, Fred Hutchinson Cancer Center

Join to view full profile

Dr. Liao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liao's full profile

Already have an account?

Office
825 Eastlake Ave E
Seattle, WA 98109
Phone+1 206-288-7222

Fax+1 206-598-6963

Education & Training

University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2007 - 2010
Yale UniversityPhD, Investigative Medicine, 2007
Yale School of MedicinePost-Doctoral Fellowship, 2002 - 2004
George Washington UniversityResidency, Obstetrics and Gynecology, 1998 - 2002
George Washington University School of Medicine and Health SciencesClass of 1998, MD
Yale UniversityBA, Molecular Biophysics and Biochemistry, 1994

Certifications & Licensure

WA State Medical License 2010 - 2025
CT State Medical License 2002 - 2010
PA State Medical License 2007 - 2010
VA State Medical License 1998 - 2002
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2017 Mar 14
Completed
Phase 1, Phase 2
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors Start of enrollment: 2017 Dec 14
Terminated
Phase 1, Phase 2
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Start of enrollment: 2019 Apr 16
Completed
Phase 1
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Start of enrollment: 2019 Apr 30
Recruiting
Phase 1
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian Start of enrollment: 2020 Jun 09
Active, not recruiting
Phase 2
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2021 Mar 18
Recruiting
Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors Start of enrollment: 2020 Aug 18
Recruiting
Phase 2
Oral AMXT 1501 Dicaprate in Combination With IV DFMO Start of enrollment: 2022 Nov 29
Recruiting
Phase 1, Phase 2
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer Start of enrollment: 2023 Nov 15
Not yet recruiting
Phase 2
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer Start of enrollment: 2022 Nov 29
Recruiting
Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies Start of enrollment: 2021 Sep 29
Recruiting
Phase 1
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Start of enrollment: 2024 Jun 01
Recruiting
Phase 2
A Study of Sovilnesib in Subjects With Ovarian Cancer Start of enrollment: 2024 Apr 04
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

24 citations
Gynecologic cancers and solid organ transplantation.
John B. Liao, Cynthia E. Fisher, Margaret M. Madeleine
American Journal of Transplantation. 2019-05-01
4 citations
Uterine lavage identifies cancer mutations and increasedsomatic mutation burden in individuals with ovarian cancer.
Talayeh S Ghezelayagh, Brendan F Kohrn, Jeanne Fredrickson, Enna Manhardt, Marc R Radke
Cancer Research Communications. 2022-10-01
57 citations
Normal labor: mechanism and duration.
John B. Liao, Catalin S. Buhimschi, Errol R. Norwitz
Obstetrics and Gynecology Clinics of North America. 2005-06-01

Lectures

Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018
Weekly Quick Hits (BioHealth Capital Region) – Week of June 5, 2023June 10th, 2023